Fig. 3: KDM4C is a JAK-inhibitor persistent functional vulnerability.
From: Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms
A Schematic depicting experimental setup of the in vitro CRISPR-Cas9 screen in JAK2-mutated HEL cells. Pharmacologic treatment was performed for 12 days with 200 nM ruxolitinib (RUX) versus DMSO control. B Dot-plot of ranked differential CRISPR-Cas9 screening hits between the RUX-treated and control condition. The Y axis shows the gene-rank, on the X axis the differential beta scores (Δbeta-scores) are plotted. RUX-“persistent” dependencies are highlighted in red.
